<DOC>
	<DOC>NCT00052065</DOC>
	<brief_summary>This is a dose-ranging, open-label, Phase 1-2a study of TLK286 in combination with Doxil in patients with platinum refractory or resistant ovarian cancer.</brief_summary>
	<brief_title>TLK286 in Combination With Doxil in Platinum Refractory or Resistant Ovarian Cancer</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<criteria>Inclusion Criteria Histologically or cytologically confirmed diagnosis of epithelial cancer of the ovary, fallopian tube cancer or primary peritoneal cancer Recurrent epithelial ovarian cancer or persistent disease following primary treatment At least one, but no more than four, prior platinumcontaining chemotherapy regimens At least one prior taxanecontaining regimen Exclusion Criteria A history of prior malignancy except for adequately treated carcinoma in situ of the uterine cervix, basal cell or squamous cell skin cancer, or other cancer for which the patient has been diseasefree for 2 years Known leptomeningeal metastases or carcinomatous meningitis Have received prior Doxil or other liposomal doxorubicin Having received whole pelvis radiation therapy</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
</DOC>